Neurocrine Biosciences, Inc. (NBIX) Q4 2018 Earnings Results

Neurocrine Biosciences Beats on EPS, Stock Down 0.78%

Neurocrine Biosciences reported a slight earnings beat, which is a positive indicator for the company. However, the stock fell by 0.78% following the announcement, suggesting that investors may have been looking for more detailed guidance or revenue figures. The lack of revenue data and forward guidance may have contributed to the stock's decline.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.19	N/A	+8.44%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the earnings per share results, highlighting their commitment to pipeline advancements. However, no specific guidance was provided for future performance.

We are pleased with our EPS performance this quarter.

Our focus remains on advancing our pipeline and delivering value.

Neurocrine Biosciences Beats on EPS, Stock Down 0.78%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Beats on EPS, Stock Down 0.78%

Key numbers

Management commentary